Sanofi provides update on Kevzara (sarilumab) Phase 3 trial in severe and critically ill COVID-19 patients outside the U.S. Sanofi and GSK agree with the UK government to supply up to 60 million doses of COVID-19 vaccine, Sanofis investigational enzyme replacement therapy shows clinically meaningful improvement in critical manifestations of late-onset Pompe disease, Sanofi and GSK will provide up to 300 million doses of COVID-19 vaccine to the European Union, Sanofi and GSK in advanced discussions with European Union to supply up to 300 million doses of COVID-19 vaccine, CHMP recommends approval of MenQuadfi for active immunization of individuals from the age of 12 months and older against invasive meningococcal ACWY disease, Sanofi to evaluate the safety and efficacy of novel investigational candidate THOR-707 and KEYTRUDA (pembrolizumab) in pursuit of establishing a new treatment option in oncology, Sanofi to launch Action 2020, a worldwide employee stock purchase plan, Dupixent (dupilumab) approved in China for adults with moderate-to-severe atopic dermatitis. The result is spontaneous or prolonged bleeding, often into the joints and soft tissues. Sanofi scientists are working to tame over-active immune responses that drive systemic, chronic diseases. If you wish to continue to this external website, click Proceed. Sally.Bain@sanofi.com, Nicolas Obrist Amunixs pipeline, which includes lead candidate, AMX-818, a masked HER2-directed TCE, offers a strong strategic fit with Sanofis focus on developing potentially transformative cancer therapies in immuno-oncology. In last few years, there has been increased interest among pharmaceutical companies for the development of novel orphan drugs against rare diseases. To protect the replacement factors from being metabolized too quickly, scientists designed them to hitch a ride on proteins that are recycled more slowly. Clinical development programs include venglustat, an oral inhibitor of glucosylceramide synthase, in Fabry Disease, Gaucher Disease Type 3, GBA Parkinson's Disease and . Under the terms of the agreement, Sanofi will acquire Amunix for an upfront payment of approximately $1 billion and up to $225 million upon achievement of certain future development milestones. This accumulation of glycogen leads to irreversible damage to the muscles, including the diaphragm muscle supporting lung function and breathing, and other skeletal muscles that affect mobility. Although individual diseases are rare, collectively, rare diseases are anything but - there are 7,000 different rare diseases and more than 400 million people suffering from them globally. Pompe disease is caused by a genetic deficiency or dysfunction of the lysosomal enzyme acid -glucosidase deficiency (GAA), which results in build-up of complex sugars (glycogen) in muscle cells throughout the body. Rare disease is disorder which affects a small percentage of total population. Sandhoff Disease Drug Research Report 2022: Comprehensive Insights About 5+ Companies and 5+ Pipeline Drugs Featuring IntraBio, Sanofi, Polaryx Therapeutics, & Azafaros - ResearchAndMarkets.com We now look forward to combining forces with Sanofis team to leverage its expertise and together serve as a center of excellence in bringing these potentially better and safer drug candidates to patients, said Volker Schellenberger, Ph.D., Co-Founder, President and Chief Technology Officer, Amunix. Investigator Sponsored Studies and Externally Sponsored Collaboration, Access to Quality Healthcare Sanofi Global Health, Contributing to the eradication, elimination and control of some infectious diseases, Serving the needs of patients with non-communicable diseases, Development opportunity: how Sanofi empowers you, Sanofi provides update on Phase 2 study evaluating amcenestrant in ER+/HER2- advanced or metastatic breast cancer, Press Release: Xenpozyme (olipudase alfa) approved in Japan, first and only approved therapy indicated to treat acid sphingomyelinase deficiency, Sanofi announces 300 million collaboration with Blackstone Life Sciences to advance an innovative treatment for multiple myeloma, Press Release: Sanofi and Seagen announce collaboration to develop and commercialize multiple novel antibody-drug conjugates, Press Release: Sanofi moves forward with EUROAPI listing on Euronext Paris, Sanofi recognized by S&P as one of the most sustainability-committed companies, Nirsevimab significantly protected infants against RSV disease in Phase 3 trial, Late-breaking data at 2022 AAAAI Annual Meeting show Dupixent (dupilumab) significantly improved signs and symptoms of eosinophilic esophagitis, Press release: Late-breaking Phase 3 data at AAD 2022 show Dupixent (dupilumab) significantly improved signs and symptoms of prurigo nodularis, Efanesoctocog alfa met primary and key secondary endpoints in pivotal study in hemophilia A, demonstrating superiority to prior factor prophylaxis treatment, Press Release: Sanofi continues on path to industry leadership in Immunology with Dupixent (dupilumab) as key driver, Press Release: Sanofi and IGM Biosciences Announce Collaboration Agreement for Oncology, Immunology and Inflammation Targets, Press Release: Availability of the Q1 2022 Memorandum for modelling purposes, Press Release: Sanofi unveils new corporate brand and logo unites the company under one purpose and a single identity, Press Release: Sanofi teams up with McLaren Racing to accelerate industrial excellence, FDA accepts Dupixent (dupilumab) for Priority Review in children aged 6 months to 5 years with moderate-to-severe atopic dermatitis, Press Release: FDA accepts Dupixent (dupilumab) for Priority Review in patients aged 12 years and older with eosinophilic esophagitis, Olipudase alfa shown to provide sustained improvement across multiple clinical manifestations of ASMD, Update on ongoing Dupixent (dupilumab) chronic spontaneous urticaria Phase 3 program, Press Release: EUROAPI listing on Euronext Paris expected on May 6, 2022, Press Release: Sanofi continues to deliver strong business EPS growth driven by higher sales and improved margins in Q1, Filing of the 2021 U.S. Form 20-F and French Document dEnregistrement Universel containing the Annual Financial Report, Exscientia and Sanofi establish strategic research collaboration to develop AI-driven pipeline of precision-engineered medicines, Nirsevimab EMA regulatory submission accepted under accelerated assessment for RSV protection in all infants, Press Release: Positive Phase 1/2 study results of rilzabrutinib in people with immune thrombocytopenia published in The New England Journal of Medicine, Sanofi and Regeneron provide regulatory update on Libtayo (cemiplimab-rwlc) in advanced cervical cancer, Press Release: Sanofi launches first-in-pharma Diversity, Equity & Inclusion Board, Press Release: Sanofi successfully priced an inaugural sustainability-linked bond indexed on access to medicines, Late-breaking phase 3 data at 2022 AAAAI Annual Meeting show Dupixent (dupilumab) significantly reduced itch and hives in patients with chronic spontaneous urticaria, Availability of the Q4 2021 Memorandum for modelling purposes, New preclinical tolebrutinib data demonstrated superior brain penetration and potency, Positive Dupixent (dupilumab) data across five diseases with underlying type 2 inflammation to be presented at 2022 AAAAI Annual Meeting, Sanofi and GSK to seek regulatory authorization for COVID-19 vaccine, Press Release: Dupixent (dupilumab) approved by European Commission for children aged 6 to 11 years with severe asthma with type 2 inflammation, Press Release: Strong 2021 sales and business EPS growth enabling increased investment in R&D, Nexviazyme (avalglucosidase alfa) shows sustained improvements in respiratory function and mobility in patients with Pompe disease, CHMP recommends approval of Dupixent (dupilumab) for children aged 6 to 11 years with severe asthma with type 2 inflammation, Second positive Phase 3 Dupixent (dupilumab) trial confirms significant improvements for patients with prurigo nodularis, FDA approves Enjaymo (sutimlimab-jome), first treatment for use in patients with cold agglutinin disease, Sanofis Board of Directors proposes the appointment of Carole Ferrand, Emile Voest and Antoine Yver as independent Directors, Media Update: Rezurock (belumosudil) patient-reported outcomes correlated with clinical response in chronic graft-versus-host disease, Press Release: Annual General Meeting of May 3, 2022, Press Release: Foundation S: Sanofis new philanthropic spearhead, Press Release: Update on Cialis Rx-to-OTC Switch Actual Use Trial, Press Release: Sarclisa (isatuximab) combination provides unprecedented median progression free survival in patients with relapsed multiple myeloma receiving a proteasome inhibitor therapy, Press Release: FDA grants efanesoctocog alfa Breakthrough Therapy designation for hemophilia A, Press Release: New nirsevimab data analyses reinforce efficacy against RSV, Press Release: FDA approves Dupixent (dupilumab) as first treatment for adults and children aged 12 and older with eosinophilic esophagitis, Media Update: New data from fast-growing innovative Oncology pipeline and portfolio to be presented at 2022 ASCO Annual Meeting, Press Release: Sanofi grants Regeneron worldwide exclusive license rights to Libtayo (cemiplimab), Media Update: CHMP recommends approval of Xenpozyme (olipudase alfa), the first and only treatment for ASMD, Press Release: FDA accepts Dupixent (dupilumab) for priority review in adults with prurigo nodularis, Sanofi launches 2022 global Employee Stock Purchase Plan for 86.000 people, Press Release: FDA approves Dupixent (dupilumab) as first biologic medicine for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis, Sanofi launches its first Digital Accelerator fueled by new talent and focused on growth, Media Update: Sanofi, a leader in immune-mediated rare blood disorders, to present latest data at EHA 2022, Press Release: Sanofi-GSK next-generation COVID-19 booster delivers strong immune response against variants of concern, including Omicron, Press Release: Sanofi-GSK first to report a successful efficacy study against Omicron with COVID-19 Beta-containing vaccine, Availability of the Q2 2022 Memorandum for modelling purposes, Press Release: Nexviadyme (avalglucosidase alfa) approved by European Commission as a potential new standard of care for the treatment of Pompe Disease, Press Release: Xenpozyme (olipudase alfa) approved by European Commission as first and only treatment for ASMD. Without enough factor VIII or IX, the body cant produce enough thrombin to activate clotting.1,2 To solve this problem, many people are treated with replacement factors, given by intravenous (IV) injection. 2022. . investor.relations@sanofi.com Structural insights into RNA processing by the human RISC-loading complex, An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia, GalNAc-siRNA Conjugates: Leading the Way for Delivery of RNAi Therapeutics, Update on clinical gene therapy for hemophilia, Continuing education course #2: current understanding of hemostasis, Seth Chhabra E, Liu T, Kulman J, et al. This article refers to therapies that are being investigated in research and development programs. Phase 2/3 adaptive-designed trial in hospitalized COVID-19 patients, Sanofi: Dupixent (dupilumab) Phase 3 data show significant improvement in severe atopic dermatitis for children aged 6 to 11 years, Sanofi successfully prices taps on outstanding bond issues for EUR 500 million, Sanofi: Information on Sanofis Shareholder General Meeting of Tuesday, April 28, 2020, Sarclisa (isatuximab) Phase 3 IKEMA trial meets primary endpoint early in patients with relapsed multiple myeloma, Sanofis Board of Directors notes the resignation of Emmanuel Babeau and coopts Gilles Schnepp as Independent Director, FDA grants priority review of sutimlimab, potential first approved treatment of hemolysis in adult patients with Cold Agglutinin Disease, Sanofi : FDA accepts for priority review Dupixent (dupilumab) for children aged 6 to 11 years with moderate-to-severe atopic dermatitis, Sanofi intends to sell its equity investment in Regeneron; confirms no change to ongoing collaboration, Sanofi and Luminostics to join forces on developing breakthrough COVID-19 smartphone-based self-testing solution, Sanofi finalizes Praluent (alirocumab) restructuring with Regeneron, Dupixent (dupilumab) eosinophilic esophagitis trial meets both co-primary endpoints, Sanofi to create new industry leading European company to provide active pharmaceutical ingredients (API*), Sanofi : Sanofi brain-penetrant BTK inhibitor meets primary endpoint of Phase 2 trial in relapsing multiple sclerosis. Sanofi to commence tender offer for acquisition of Principia Biopharma Inc. Data presented at WORLDSymposiumTM reinforces robust rare disease pipeline and highlights additional clinical data for investigational avalglucosidase alfa in Pompe disease; Sanofi completes Kymab acquisition; Filing of the 2020 U.S. Form 20-F and French "Document d'Enregistrement Universel" containing the Annual Financial Report Sanofi will purchase . We stand by the few who suffer from rare diseases and the millions with long-term chronic . In some chronic inflammatory diseases, two types of T-helper immune cells (Th1/17) can trigger several types of inflammation, leading to a hyperactive immune system that attacks healthy tissues. These projects represent new molecular entities as well as existing therapeutics . Media Update: Patient enrollment of phase III tolebrutinib trials paused in the U.S. Sanofi Global Health launches nonprofit Impact brand for 30 medicines in low-income countries, Press Release: Fitusiran prophylaxis reduced bleeds by 61% in people with hemophilia A or B, with or without inhibitors, compared to prior factor or bypassing agent prophylaxis, Press Release: Pivotal data demonstrate once-weekly efanesoctocog alfa provides superior bleed protection compared to prior factor prophylaxis, Press Release: Dupixent (dupilumab) Phase 3 trial shows positive results in children 1 to 11 years of age with eosinophilic esophagitis, Press Release: Strong execution in Q2 drives full-year 2022 guidance upgrade and delivers rich R&D news flow in Immunology and Rare Disease, Press Release: Sanofi and Innovent Biologics enter strategic collaboration to accelerate development of oncology medicines and expand presence in China, Media Update: Tolebrutinib clinical trial program update, Press Release: Sanofi provides update on amcenestrant clinical development program, Media Update: New Dupixent (dupilumab) data at ERS adds to body of safety and efficacy data in chronic respiratory diseases, Press Release: FDA grants priority review to efanesoctocog alfa for people with hemophilia A, Press Release: XenpozymeTM (olipudase alfa-rpcp) approved by FDA as first disease-specific treatment for ASMD (non-CNS manifestations), Press Release: Evolution of the Board of Directors, Press Release: Late-breaking Dupixent (dupilumab) data at ERS 2022 show consistent efficacy and safety profile for up to two years in children aged 6 to 11 years with moderate-to-severe asthma, Media Update: New Dupixent (dupilumab) data at EADV 2022 adds to body of evidence across multiple inflammatory skin diseases, Press Release: Dupixent (dupilumab) late-breaking Phase 3 data at EADV 2022 showed significant improvements in signs and symptoms of prurigo nodularis, Media Update: Positive Dupixent (dupilumab) Phase 3 data in children aged 6 months to 5 years with moderate-to-severe atopic dermatitis published in The Lancet, Press Release: CHMP recommends approval of Beyfortus (nirsevimab) for prevention of RSV disease in infants, Media Update: CHMP recommends approval of Enjaymo (sutimlimab), first and only approved treatment for hemolytic anemia in adult patients with cold agglutinin disease, Press Release: Availability of the Q3 2022 Memorandum for modelling purposes, Press Release: Dupixent (dupilumab) approved by FDA as the first and only treatment indicated for prurigo nodularis, Press Release: Dupixent (dupilumab) late-breaking Phase 3 data presented at UEG Week 2022 showed significant histological remission of eosinophilic esophagitis (EoE) in children 1 to 11 years old, Media Update: New two-year efficacy and safety data for tolebrutinib, Sanofis investigational, brain-penetrant and bioactive BTK inhibitor, to be presented at ECTRIMS 2022, Press Release: Continued strong growth in Q3 with key regulatory milestones achieved, Press Release: European Commission grants first approval worldwide of Beyfortus (nirsevimab) for prevention of RSV disease in infants, Sarclisa (isatuximab) trial is first Phase 3 study to meet primary endpoint of minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma, Vaccines Investor Event: Sanofi reiterates confidence in strong growth outlook and showcases pipeline of innovative vaccine candidates, Sanofi to acquire Origimm Biotechnology in first move to treat acne with vaccine-based immunotherapy, Data from two Phase 3 studies demonstrating fitusiran significantly reduced bleeds in people with hemophilia A or B, with or without inhibitors, were featured at ASHs plenary and late-breaking sessions, New England Journal of Medicine publishes positive Phase 3 Dupixent (dupilumab) results in children with moderate-to-severe asthma, Positive Phase 3 Dupixent (dupilumab) data in children 6 months to 5 years with moderate-to-severe atopic dermatitis featured in RAD 2021 late-breaking session, Sanofi and GSK announce positive preliminary booster data for their COVID-19 vaccine candidate and continuation of Phase 3 trial per independent Monitoring Board recommendation, Sanofi announces results of CHMP re-examination of the New Active Substance status for avalglucosidase alfa, a potential new standard of care for the treatment of Pompe disease, Sanofi invests $180 million equity in Owkins artificial intelligence and federated learning to advance oncology pipeline, EMA accepts regulatory submission for olipudase alfa, the first potential therapy for ASMD, Press Release: Gilles SCHNEPP takes over as Chairman of the Appointments, Governance and CSR Committee of Sanofi, Sanofi completes acquisition of Translate Bio, accelerating the application of mRNA in new vaccines and therapeutics, Sanofi: Availability of the Q2 2021 Memorandum for modelling purposes, Sanofi to focus its COVID-19 development efforts on the recombinant vaccine candidate, Sanofi: Availability of the Q3 2021 Memorandum for modelling purposes, Sanofi: Libtayo (cemiplimab) approved by the European Commission as the first immunotherapy indicated for patients with advanced basal cell carcinoma, ESMO late-breaking data show Libtayo (cemiplimab) and chemotherapy first-line treatment combination significantly improved overall survival in patients with advanced NSCLC, Second Dupixent (dupilumab) Phase 3 eosinophilic esophagitis trial to demonstrate significant disease improvements, underscoring role of type 2 inflammation in this complex disease, Sanofi highlights scientific innovations in the field of rare blood disorders at ISTH 2021, Sanofi continues streamlining of established products with sale of dental care brands to Septodont, Sanofi launches its new global employee share ownership plan, Sanofi: Positive results from the first study of high-dose influenza vaccine with a COVID-19 mRNA booster support co-administration recommendations, MenQuadfi demonstrates superior immune response against serogroup C meningococcal disease in toddlers, Libtayo (cemiplimab) receives positive CHMP opinion for the treatment in Europe of two advanced cancers, Sanofi announces positive Phase 1/2 study interim results for its first mRNA-based vaccine candidate, Sanofi partnering with leading academic cooperative groups to study amcenestrant in the adjuvant setting for patients with estrogen receptor positive breast cancer, Sanofi and Translate Bio initiate Phase 1 clinical trial of mRNA influenza vaccine, European Commission approves Aubagio (teriflunomide) as the first oral MS therapy for first-line treatment of children and adolescents living with relapsing-remitting multiple sclerosis, FDA approves Nexviazyme (avalglucosidase alfa-ngpt), an important new treatment option for late-onset Pompe disease, Sanofi and GSK initiate global Phase 3 clinical efficacy study of COVID-19 vaccine candidate, New, late-breaking data at EADV highlights emerging clinical profile of amlitelimab (formerly KY1005) in adults with inadequately controlled moderate-to-severe atopic dermatitis, Sanofi: Libtayo (cemiplimab) approved by the European Commission for first-line treatment of patients with advanced non-small cell lung cancer with 50% PD-L1 expression, Dupixent (dupilumab) pivotal trial meets all primary and secondary endpoints becoming first biologic medicine to significantly reduce signs and symptoms of moderate-to-severe atopic dermatitis in children as young as 6 months, Sanofi: Strong Q3 performance drives guidance upgrade to around 14% business EPS growth at CER(1), Sanofi and GSK COVID-19 vaccine candidate demonstrates strong immune responses across all adult age groups in Phase 2 trial, New long-term data reinforcing promising safety and efficacy profile of brain-penetrant tolebrutinib presented at ECTRIMS 2021. Venglustat is an investigational oral glucosylceramide synthase inhibitor in development for multiple diseases with disruptions in the GSL metabolic pathway. In November 2020, the U.S. Food and Drug Administration (FDA) accepted for Priority Review the Biologics License Application (BLA) for avalglucosidase alfa for long-term enzyme replacement therapy for the treatment of patients with Pompe disease. Data with investigational enzyme replacement therapy avalglucosidase alfa in late-onset Pompe disease (LOPD) and infantile-onset Pompe disease (IOPD) will be featured as platform and poster presentations at the 17th annual WORLDSymposiumTM, to be held February 8-12, 2021. Availability of the Pre-quarterly Results Communication, Sanofi to present Phase 3 results of avalglucosidase alfa in patients with late-onset Pompe disease, FDA grants Dupixent (dupilumab) Breakthrough Therapy designation for eosinophilic esophagitis, Sanofi H1 2020 business EPS(1) growth of 9.2%(2) driven by transformation, Sanofi and GSK selected for Operation Warp Speed to supply United States government with 100 million doses of COVID-19 vaccine. The FDA also granted Breakthrough Therapy and Fast Track designations to avalglucosidase alfa. bi-specific antibodies for solid tumors, including unwanted immune attack of normal healthy cells and systematic widespread immune system activation that leads to side effects such as Cytokine Release Syndrome. These GSLs are fatty substances essential for maintaining the cell membranes. :+1 (781) 264-1091 Data at WORLD Symposium that feature other investigational therapies from Sanofi's robust rare disease pipeline, as well as historical, real-world evidence gathered in disease registries: Avalglucosidase alfa has not been approved by any regulatory authority and its safety and efficacy are still being evaluated. Hart-Scott-Rodino waiting period expires for Sanofis acquisition of Principia Biopharma Inc. EMA accepts regulatory submission for avalglucosidase alfa, a potentially new standard of care enzyme replacement therapy for Pompe disease, Sanofi offers to acquire Kiadis, a clinical-stage company developing cell-based immunotherapy products, CHMP recommends approval of Dupixent (dupilumab) for children aged 6 to 11 years with severe atopic dermatitis, Sanofi and Translate Bio mRNA COVID-19 vaccine candidate induced high antibody levels in preclinical studies, Sanofi and GSK to support COVAX with 200 million doses of adjuvanted, recombinant protein-based COVID-19 vaccine, New England Journal of Medicine publishes positive final results from Phase 1/2a study of BIVV001 in people with severe hemophilia A, European Commission approves Sarclisa (isatuximab) for adults with relapsed and refractory multiple myeloma, Sanofi completes Principia Biopharma Inc. acquisition, Dupixent (dupilumab) significantly reduced severe asthma attacks in children and is the only biologic to demonstrate improvement in childrens lung function in a randomized Phase 3 trial, Sarclisa (isatuximab) combination therapy demonstrated superior progression free survival and clinically meaningful depth of response in patients with relapsed multiple myeloma, Sanofi offers to acquire Kiadis for 308 million, Late-breaking ESMO presentation shows Libtayo (cemiplimab) monotherapy increases overall survival in first-line advanced non-small cell lung cancer with PD-L1 expression of 50%, Sanofi invests to make France its world class center of excellence in vaccine research and production, Sanofi Q3 2020 business EPS(1) growth of 8.8% at CER, Dupixent (dupilumab) long-term data show sustained improvement in lung function and reduction in severe exacerbations in adults and adolescents with moderate-to-severe asthma, Dupixent (dupilumab) late-breaking pivotal data showing significant improvement in eosinophilic esophagitis signs and symptoms presented for the first time at scientific meetings, Sanofi announces closing of Regeneron stock sale, New clinical and health-related quality of life data in multiple myeloma and rare blood disorders to be presented at ASH 2020, Safety and efficacy of Dupixent (dupilumab) in patients as young as 6 years with moderate-to-severe atopic dermatitis further reinforced by new data analyses presented at EADV, Sanofis virtual R&D Day event to highlight capabilities, platforms, and expertise in disease pathways to deliver potentially transformative treatments to patients, Sanofi to present growth opportunities and development strategy for Dupixent (dupilumab) in type 2 inflammatory diseases, CHMP recommends approval of Supemtek (quadrivalent recombinant influenza vaccine) for the prevention of influenza in adults aged 18 years and older, European Patent Office rules in favor of Sanofi and Regeneron concerning Praluent (alirocumab), Positive pivotal data for Libtayo (cemiplimab) monotherapy in locally advanced basal cell carcinoma featured as a late-breaking presentation at ESMO, Online availability of Sanofis half-year financial report for 2020, Dr. Jean-Christophe Rufin appointed President of the Sanofi Espoir Corporate Foundation, Sanofi and GSK initiate Phase 1/2 clinical trial of COVID-19 adjuvanted recombinant protein-based vaccine candidate, Sanofi announces positive long-term efficacy and safety data for fitusiran from interim analysis of Phase 2 extension study in people with hemophilia A and B, with or without inhibitors, Availability of the Q3 2020 Memorandum for modelling purposes, Sanofi and Regeneron provide update on Kevzara (sarilumab) Phase 3 U.S. trial in COVID-19 patients, Sanofi and GSK sign agreements with the Government of Canada to supply up to 72 million doses of adjuvanted COVID-19 vaccine, Nirsevimab reduced respiratory syncytial virus infections requiring medical care in healthy premature infants in Phase 2b trial, Sanofi to present oncology strategy, provide update on portfolio and emerging pipeline, Sanofi and Translate Bio expand collaboration to develop mRNA vaccines across all infectious disease areas, Sanofi : FDA approves Sarclisa (isatuximab-irfc) for patients with relapsed refractory multiple myeloma, COVID-19: Sanofi to donate 100 million doses of hydroxychloroquine across 50 countries, Sanofi : Filing of the 2019 U.S. Form 20-F and French Document dEnregistrement Universel containing the Annual Financial Report, Sanofi : Availability of the Pre-quarterly Results Communication, Sanofi announces pricing of Regeneron stock offering, Sanofi: FDA approves Dupixent (dupilumab) as first biologic medicine for children aged 6 to 11 years with moderate-to-severe atopic dermatitis, Sanofi joins forces with U.S. Department of Health and Human Services to advance a novel coronavirus vaccine, Sanofi: First patient outside U.S. treated in global Kevzara (sarilumab) clinical trial program for patients with severe COVID-19, Sanofi to present Phase 2 detailed results of its brain-penetrant BTK inhibitor in relapsing multiple sclerosis, Sanofi and Translate Bio collaborate to develop novel mRNA vaccine candidate against COVID-19, Sanofi: Annual General Meeting of April 28, 2020, Libtayo (cemiplimab) shows clinically meaningful and durable responses in second-line advanced basal cell carcinoma, Sanofi's Board of Directors proposes the appointment of Rachel Duan and Lise Kingo as independent directors, Sanofi to highlight pipeline programs in a series of interactive virtual sessions leading to a R&D day event, Sanofi delivers strong 2019 business EPS growth of 6.8% at CER, Sanofi: Phase 3 trial of Libtayo (cemiplimab) as monotherapy for first-line advanced non-small cell lung cancer stopped early due to highly significant improvement in overall survival, Sanofi and GSK to join forces in unprecedented vaccine collaboration to fight COVID-19, Sanofi names new leaders to Executive Committee, Sanofi: Availability of the Pre-quarterly Results Communication, Sanofi brain-penetrant BTK inhibitor significantly reduced disease activity in Phase 2 trial in relapsing multiple sclerosis, Libtayo (cemiplimab-rwlc) longer-term results in advanced cutaneous squamous cell carcinoma presented at ASCO 2020 show durable responses that deepen over time, FDA approves MenQuadfiTM, the latest innovation in meningococcal (MenACWY) vaccination, Sanofi successfully prices EUR 1.5 billion of bond issue, Sanofi receives positive CHMP opinion for Sarclisa (isatuximab) for the treatment of relapsed and refractory multiple myeloma, Sanofi : Positive topline results demonstrated by olipudase alfa, first and only investigational therapy in late-stage development for acid sphingomyelinase deficiency, Sanofi and Regeneron provide update on U.S.
Quarter System College, Spring Boot Rest Controller Get Ip Address, Day Festivals London 2022, Rc Airplane Wheels And Tires, Walking Street In Ho Chi Minh City,